Key result
CRT shows similar heart failure hospitalization and mortality benefits between NYHA III and IV patients.
Why the study?
Data on the benefits of cardiac resynchronization therapy (CRT) in patients with severe heart failure symptoms are limited.
Does cardiac resynchronization therapy reduce heart failure hospitalization or all-cause mortality differently in patients with ambulatory NYHA class IV versus NYHA class III heart failure?
Meta-Analysis (n=2,309)
Yes
Does cardiac resynchronization therapy reduce heart failure hospitalization or all-cause mortality differently in patients with ambulatory NYHA class IV versus NYHA class III heart failure?
Effect estimate: ratio of aHR 0.72 (95% CI 0.30-1.27)
p-value: p=0.23
Cardiac resynchronization therapy provides similar relative benefits for reducing heart failure hospitalization or all-cause mortality in patients with ambulatory NYHA class IV compared to those with NYHA class III heart failure.
No takes yet. Share an insight, caveat, or question.
Supports CRT consideration in ambulatory NYHA IV; confirms similar relative benefits as in NYHA III.
Shivakumar et al. (2024) conducted a meta-analysis in Heart failure (n=2,309). Cardiac resynchronization therapy vs. NYHA III vs NYHA IV was evaluated on time to the composite end point of the first heart failure hospitalization or all-cause mortality (ratio of aHR 0.72, 95% CI 0.30-1.27, p=0.23). Cardiac resynchronization therapy benefits for heart failure hospitalization or mortality did not differ significantly between NYHA III and IV patients (ratio of aHR 0.72; 95% CI 0.30-1.27; P=0.23).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: